CN108368101B - 选择性nr2b拮抗剂 - Google Patents
选择性nr2b拮抗剂 Download PDFInfo
- Publication number
- CN108368101B CN108368101B CN201680073103.8A CN201680073103A CN108368101B CN 108368101 B CN108368101 B CN 108368101B CN 201680073103 A CN201680073103 A CN 201680073103A CN 108368101 B CN108368101 B CN 108368101B
- Authority
- CN
- China
- Prior art keywords
- flow rate
- column
- compound
- mobile phase
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3309/DEL/2015 | 2015-10-14 | ||
| IN3309DE2015 | 2015-10-14 | ||
| PCT/US2016/056716 WO2017066368A1 (en) | 2015-10-14 | 2016-10-13 | Selective nr2b antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108368101A CN108368101A (zh) | 2018-08-03 |
| CN108368101B true CN108368101B (zh) | 2022-03-15 |
Family
ID=57208377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680073103.8A Active CN108368101B (zh) | 2015-10-14 | 2016-10-13 | 选择性nr2b拮抗剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10501451B2 (enExample) |
| EP (1) | EP3362447B1 (enExample) |
| JP (1) | JP6843853B2 (enExample) |
| KR (1) | KR20180064507A (enExample) |
| CN (1) | CN108368101B (enExample) |
| AU (1) | AU2016340239A1 (enExample) |
| BR (1) | BR112018007181A2 (enExample) |
| CA (1) | CA3001894A1 (enExample) |
| EA (1) | EA201890764A1 (enExample) |
| ES (1) | ES2822830T3 (enExample) |
| IL (1) | IL258611A (enExample) |
| MX (1) | MX2018004257A (enExample) |
| WO (1) | WO2017066368A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3001890A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| JP7093469B2 (ja) * | 2018-10-17 | 2022-06-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用 |
| TW202035395A (zh) * | 2018-10-17 | 2020-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 4-嘧啶-5-基甲基-嗎啉衍生物及其作為藥物之用途 |
| PE20211278A1 (es) * | 2018-10-17 | 2021-07-19 | Boehringer Ingelheim Int | Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento |
| US12398143B2 (en) | 2019-06-04 | 2025-08-26 | Boehringer Ingelheim International Gmbh | Imidazopyrazine derivatives and the use thereof as medicament |
| MX2023006567A (es) * | 2020-12-04 | 2023-06-16 | Novartis Ag | Regimen de dosificacion para un nam del receptor nr2b-nmda para el tratamiento de la depresion. |
| CN113620896A (zh) * | 2021-08-31 | 2021-11-09 | 青岛科技大学 | 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法 |
| CN116063200A (zh) * | 2022-12-12 | 2023-05-05 | 华南理工大学 | 一种异噁唑啉宠物用杀虫剂氟雷拉纳中间体及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070185168A1 (en) * | 2004-04-07 | 2007-08-09 | Takai Haruki S | Piperidine derivatives |
| WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
| WO2015105772A1 (en) * | 2014-01-09 | 2015-07-16 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| WO2015105929A1 (en) * | 2014-01-09 | 2015-07-16 | Bristol-Myers Squibb Company | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| US7022728B2 (en) | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| CA2527093C (en) | 2003-06-04 | 2009-10-20 | Merck & Co., Inc. | 3-fluoro-piperidines as nmda/nr2b antagonists |
| MXPA06003748A (es) | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| JPWO2006137465A1 (ja) * | 2005-06-24 | 2009-01-22 | 塩野義製薬株式会社 | 含窒素複素環誘導体 |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| CN103497114A (zh) | 2007-06-29 | 2014-01-08 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| JP2009067784A (ja) * | 2007-08-21 | 2009-04-02 | Shionogi & Co Ltd | 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤 |
-
2016
- 2016-10-13 WO PCT/US2016/056716 patent/WO2017066368A1/en not_active Ceased
- 2016-10-13 CN CN201680073103.8A patent/CN108368101B/zh active Active
- 2016-10-13 US US15/767,385 patent/US10501451B2/en active Active
- 2016-10-13 AU AU2016340239A patent/AU2016340239A1/en not_active Abandoned
- 2016-10-13 KR KR1020187013128A patent/KR20180064507A/ko active Pending
- 2016-10-13 JP JP2018519276A patent/JP6843853B2/ja not_active Expired - Fee Related
- 2016-10-13 EP EP16787974.1A patent/EP3362447B1/en active Active
- 2016-10-13 MX MX2018004257A patent/MX2018004257A/es unknown
- 2016-10-13 BR BR112018007181A patent/BR112018007181A2/pt not_active Application Discontinuation
- 2016-10-13 ES ES16787974T patent/ES2822830T3/es active Active
- 2016-10-13 CA CA3001894A patent/CA3001894A1/en not_active Abandoned
- 2016-10-13 EA EA201890764A patent/EA201890764A1/ru unknown
-
2018
- 2018-04-10 IL IL258611A patent/IL258611A/en unknown
-
2019
- 2019-12-09 US US16/707,382 patent/US10954225B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070185168A1 (en) * | 2004-04-07 | 2007-08-09 | Takai Haruki S | Piperidine derivatives |
| WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
| WO2015105772A1 (en) * | 2014-01-09 | 2015-07-16 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| WO2015105929A1 (en) * | 2014-01-09 | 2015-07-16 | Bristol-Myers Squibb Company | (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
Non-Patent Citations (2)
| Title |
|---|
| Novel analogues of ketamine and phencyclidine as NMDA receptor antagonists;Paola Zarantonello et al.，;《Bioorganic & Medicinal Chemistry Letters》;20110218;第21卷;第2059-2063页 * |
| 芳甲酰烷基哌嗪类化合物的合成及抗脑缺氧缺血活性;李建其等;《中国药物化学杂志》;20060228;第16卷(第1期);第6-14页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3362447A1 (en) | 2018-08-22 |
| US20180312495A1 (en) | 2018-11-01 |
| IL258611A (en) | 2018-06-28 |
| ES2822830T3 (es) | 2021-05-05 |
| EP3362447B1 (en) | 2020-08-26 |
| US10501451B2 (en) | 2019-12-10 |
| JP2018530582A (ja) | 2018-10-18 |
| US10954225B2 (en) | 2021-03-23 |
| MX2018004257A (es) | 2018-05-16 |
| CN108368101A (zh) | 2018-08-03 |
| AU2016340239A1 (en) | 2018-05-31 |
| EA201890764A1 (ru) | 2018-09-28 |
| JP6843853B2 (ja) | 2021-03-17 |
| CA3001894A1 (en) | 2017-04-20 |
| WO2017066368A1 (en) | 2017-04-20 |
| US20200115370A1 (en) | 2020-04-16 |
| BR112018007181A2 (pt) | 2018-10-16 |
| KR20180064507A (ko) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108368101B (zh) | 选择性nr2b拮抗剂 | |
| AU2014212487B2 (en) | Spiro-lactam NMDA receptor modulators and uses thereof | |
| TW202341983A (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| ES2672992T3 (es) | Compuesto aromático | |
| KR102311518B1 (ko) | 선택적 nr2b 길항제 | |
| TWI851226B (zh) | 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 | |
| CN112236423A (zh) | 哌啶基-3-(芳氧基)丙酰胺和丙酸酯 | |
| TW202204342A (zh) | Ｎ—（雜環基及雜環基烷基）—３—苯甲基吡啶—２—胺衍生物 | |
| JP2018536637A (ja) | 選択的ｎｒ２ｂアンタゴニスト | |
| AU2021291799A1 (en) | Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro(3,4- b)pyridine-3-carboxylate compounds as Cav1.2 activators | |
| CN112867508B (zh) | 4-吡啶基甲基-吗啉衍生物及其作为药物的用途 | |
| WO1995025100A1 (fr) | Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes | |
| WO2024233747A1 (en) | Heteroaryl compounds as ligand directed degraders of irak4 | |
| KR20250086775A (ko) | 파타틴-유사 인산지질분해효소 도메인-함유 단백질 3(pnpla3) 개질제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |